Analyst Price Target is $22.00
▲ +130.37% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Daxor in the last 3 months. The average price target is $22.00, with a high forecast of $22.00 and a low forecast of $22.00. The average price target represents a 130.37% upside from the last price of $9.55.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Daxor.
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage and andrology services, such as semen analysis, sperm washing, and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in Oak Ridge, TN.